<div id="readability-page-1"><p>Yousif Capital Management LLC boosted its stake in  Sanofi (NASDAQ:SNY - Free Report) by 11.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor  owned 66,980 shares of the company's stock after acquiring an additional 6,789 shares during the quarter. Yousif Capital Management LLC's holdings in Sanofi were worth $3,236,000 as of its most recent SEC filing.</p><ul><li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li></ul><p>Several other institutional investors have also added to or reduced their stakes in SNY. Ameritas Advisory Services LLC bought a new stake in  Sanofi in the 2nd quarter valued at $28,000.  Accent Capital Management LLC bought a new stake in  Sanofi in the 1st quarter valued at $29,000.  Eastern Bank lifted its position in  Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock valued at $30,000 after acquiring an additional 300 shares in the last quarter.  Banque Transatlantique SA bought a new stake in  Sanofi in the 1st quarter valued at $33,000.  Finally, Golden State Wealth Management LLC lifted its position in  Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock valued at $35,000 after acquiring an additional 545 shares in the last quarter. 14.04% of the stock is owned by institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several equities research analysts recently commented on SNY shares. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, September 2nd. JPMorgan Chase &amp; Co. raised shares of Sanofi from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating in a research report on Friday, August 8th. Barclays  reissued an &#34;overweight&#34; rating on shares of Sanofi in a research report on Wednesday, July 2nd. Weiss Ratings  reissued a &#34;hold (c)&#34; rating on shares of Sanofi in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Sanofi from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, August 2nd. Two analysts have rated the stock with a Strong Buy rating, six have assigned  a Buy rating and two have issued  a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average target price of $62.67.</p><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p><b>View Our Latest Report on SNY</b></p><h2>Sanofi Stock Up 2.2%</h2><p>Shares of SNY stock opened at $50.02 on Friday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm's 50-day moving average is $48.42 and its 200-day moving average is $49.65. The stock has a market cap of $122.82 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.19 and a beta of 0.51. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. </p><ul><li>Regeneron: Is It the Perfect Biotech Stock for Value and Growth?</li></ul><p>Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). The firm had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm's revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period in the previous year, the company posted $1.73 earnings per share.  Sell-side analysts predict that  Sanofi will post 4.36 EPS for the current year. </p><h2>Sanofi Company Profile</h2> (Free Report)<p>Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.</p><h2>See Also</h2><ul><li>Five stocks we like better than Sanofi</li><li>5 Top Rated Dividend Stocks to Consider</li><li>Salesforce’s Long-Awaited Inflection is Here: Rally On!</li><li>How is Compound Interest Calculated?</li><li>Rocket Lab USA Receives Wall Street Validation: Time to Buy?</li><li>Best Stocks Under $10.00 </li><li>Archer Buys Rival's Patent Treasure Trove in Strategic Move</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U05Z"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Sanofi Right Now?</h2><p>Before you consider Sanofi, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.</p><p>While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SNYNF

<p>Yousif Capital Management LLC increased its stake in Sanofi (NASDAQ:SNY) by 11.3% in Q2, acquiring an additional 6,789 shares, bringing its total to 66,980 shares valued at $3.236 million. Other institutional investors also adjusted their stakes in Sanofi. Analysts have upgraded the stock's rating, with an average target price of $62.67. Sanofi's stock opened at $50.02, with a market cap of $122.82 billion. The company reported Q2 earnings of $0.90 per share, missing estimates, with revenue of $11.34 billion, down 7% year-over-year.</p>

Yousif Capital Management LLC Buys 6,789 Shares of Sanofi $SNY